Hybrid Capture–Based Genomic Profiling of Circulating Tumor DNA from Patients with Advanced Non–Small Cell Lung Cancer
Open Access
- 1 February 2019
- journal article
- research article
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 14 (2) , 255-264
Abstract
No abstract availableKeywords
Funding Information
- AbbVie
- Takeda Pharmaceuticals U.S.A.
- Pfizer
- Merck
- Novartis
- Celgene
- North Carolina GlaxoSmithKline Foundation
- National Cancer Institute
This publication has 38 references indexed in Scilit:
- Clinical next‐generation sequencing in patients with non–small cell lung cancerCancer, 2014
- Comprehensive molecular profiling of lung adenocarcinomaNature, 2014
- An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverageNature Medicine, 2014
- Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencingNature Biotechnology, 2013
- Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancerNature Medicine, 2013
- Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung CancersClinical Cancer Research, 2013
- The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics DataCancer Discovery, 2012
- Frequent and Focal FGFR1 Amplification Associates with Therapeutically Tractable FGFR1 Dependency in Squamous Cell Lung CancerScience Translational Medicine, 2010
- MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 SignalingScience, 2007
- A Gain-of-Function Mutation ofJAK2in Myeloproliferative DisordersNew England Journal of Medicine, 2005